| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 62.58B | 63.63B | 59.55B | 101.17B | 81.29B | 41.65B |
| Cost of revenue | 16.07B | 17.85B | 24.95B | 34.34B | 30.82B | 8.48B |
| Gross profit | 46.51B | 45.78B | 34.60B | 66.83B | 50.47B | 33.17B |
| Research and development | 10.44B | 10.82B | 10.68B | 11.43B | 10.36B | 8.71B |
| Selling, general and admin | 13.79B | 14.73B | 14.77B | 13.68B | 12.70B | 11.60B |
| Interest expense | 2.67B | 3.09B | 2.21B | 1.24B | 1.29B | 1.45B |
| Income before tax | 7.52B | 8.02B | 1.06B | 34.73B | 24.31B | 7.04B |
| Income tax | -266.00M | -28.00M | -1.11B | 3.33B | 1.85B | 370.00M |
| Net income | 7.77B | 8.03B | 2.12B | 31.37B | 21.98B | 9.16B |
| EPS | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 | 1.65 |
| EPS (diluted) | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | 1.63 |
| Diluted shares | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B |
| Dividends per share | 1.72 | 1.69 | 1.65 | 1.61 | 1.57 | 1.53 |
From Pfizer's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.